eHealth Initiative

ehidc.org

eHealth Initiative and Foundation (eHI) is a Washington DC-based, independent, non-profit organization whose mission is to drive improvements in the quality, safety, and efficiency of healthcare through information technology. eHI is a multi-stakeholder collaborative, convening executives from every group in healthcare, to discuss, identify, and share best practices that transform the delivery of healthcare. Working with its membership, eHI advocates for the use of health IT that is practical, sustainable, and addresses stakeholder needs, particularly those of patients.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharmacy Market

VALEMETOSTAT NEW DRUG APPLICATION SUBMITTED IN JAPAN FOR TREATMENT OF PATIENTS WITH ADULT T-CELL LEUKEMIA/LYMPHOMA

Daiichi Sankyo | December 29, 2021

news image

Daiichi Sankyo Company, Limited announced that it has submitted a New Drug Application to Japan’s Ministry of Health, Labour and Welfare for valemetostat, a potential first-in-class dual inhibitor of EZH1 and EZH2, for the treatment of patients with relapsed/refractory adult T-cell leukemia/lymphoma. ATL is a rare and aggressive type of peripheral T-cell lymphoma that occurs with greater frequency in parts of Japan and other regions.1,2 Patients with ATL face a poor prognosi...

Read More

Pharmacy Market

RX-360 LAUNCHES NEW AUDITSPLUS®

Rx-360 | June 10, 2021

news image

Rx-360, a global pharmaceutical consortium committed to supply chain integrity and patient safety, is happy to announce the extension of our Audit Program. The release of the new Rx-360 auditsPlus database is the key driver of this growth. This interactive, user-friendly database will not only raise awareness of the Rx-360 Joint Audit Program®. Still, it will also provide Rx-360 program users with new and improved tools to minimize their audit burden. Rx-360's CEO, Jim Fri...

Read More

Pharmacy Market

EAGLE PHARMACEUTICALS AGREED TO ACQUIRE ACACIA PHARMA GROUP PLC

Eagle Pharmaceuticals, Inc. | March 29, 2022

news image

Eagle Pharmaceuticals, Inc. reported that it had achieved an agreement with Acacia Pharma Group plc on the parameters of a plan of arrangement under Part 26 of the United Kingdom's Companies Act 2006. Acacia Pharma's current issued and to be issued, share capital is valued at approximately €94,700,000, or the equivalent of €0.90 per share, under the terms of the proposed transaction. Each Acacia Pharma shareholder would get €0.68 in cash and 0.0049 shares of...

Read More

USA TO DO A CLINICAL TEST OF THE JAPANESE ANTI-FLU DRUG AVIGAN TO TREAT THE PATIENTS SUFFERING FROM CORONAVIRUS

Clout News | April 12, 2020

news image

The number of positive cases of coronavirus are on a rising spree all over the world. The confirmed cases of COVID-19 on a global scale have crossed 1.7 million with the death toll crossing 1,08,000. The most affected country because of coronavirus is the United States of America. With around 5,33,378 positive cases in USA, its death toll has reached more than 20,600 leaving Italy’s death toll behind. According to the reports, USA recorded over 2,000 deaths because of COVID-19. The country...

Read More
news image

Pharmacy Market

VALEMETOSTAT NEW DRUG APPLICATION SUBMITTED IN JAPAN FOR TREATMENT OF PATIENTS WITH ADULT T-CELL LEUKEMIA/LYMPHOMA

Daiichi Sankyo | December 29, 2021

Daiichi Sankyo Company, Limited announced that it has submitted a New Drug Application to Japan’s Ministry of Health, Labour and Welfare for valemetostat, a potential first-in-class dual inhibitor of EZH1 and EZH2, for the treatment of patients with relapsed/refractory adult T-cell leukemia/lymphoma. ATL is a rare and aggressive type of peripheral T-cell lymphoma that occurs with greater frequency in parts of Japan and other regions.1,2 Patients with ATL face a poor prognosi...

Read More
news image

Pharmacy Market

RX-360 LAUNCHES NEW AUDITSPLUS®

Rx-360 | June 10, 2021

Rx-360, a global pharmaceutical consortium committed to supply chain integrity and patient safety, is happy to announce the extension of our Audit Program. The release of the new Rx-360 auditsPlus database is the key driver of this growth. This interactive, user-friendly database will not only raise awareness of the Rx-360 Joint Audit Program®. Still, it will also provide Rx-360 program users with new and improved tools to minimize their audit burden. Rx-360's CEO, Jim Fri...

Read More
news image

Pharmacy Market

EAGLE PHARMACEUTICALS AGREED TO ACQUIRE ACACIA PHARMA GROUP PLC

Eagle Pharmaceuticals, Inc. | March 29, 2022

Eagle Pharmaceuticals, Inc. reported that it had achieved an agreement with Acacia Pharma Group plc on the parameters of a plan of arrangement under Part 26 of the United Kingdom's Companies Act 2006. Acacia Pharma's current issued and to be issued, share capital is valued at approximately €94,700,000, or the equivalent of €0.90 per share, under the terms of the proposed transaction. Each Acacia Pharma shareholder would get €0.68 in cash and 0.0049 shares of...

Read More
news image

USA TO DO A CLINICAL TEST OF THE JAPANESE ANTI-FLU DRUG AVIGAN TO TREAT THE PATIENTS SUFFERING FROM CORONAVIRUS

Clout News | April 12, 2020

The number of positive cases of coronavirus are on a rising spree all over the world. The confirmed cases of COVID-19 on a global scale have crossed 1.7 million with the death toll crossing 1,08,000. The most affected country because of coronavirus is the United States of America. With around 5,33,378 positive cases in USA, its death toll has reached more than 20,600 leaving Italy’s death toll behind. According to the reports, USA recorded over 2,000 deaths because of COVID-19. The country...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us